Oruka Therapeutics has a higher consensus rating and stronger institutional ownership despite lower revenue and earnings than competitors.

Oruka Therapeutics (ORKA) specializes in genetically-targeted therapies for heart failure and cardiovascular diseases. Despite lower revenue and earnings than competitors, it has a stronger consensus rating and higher institutional ownership at 56.4%. Oruka excels in 10 of 13 comparison factors but trades at a higher price-to-earnings ratio. In contrast, Intellia Therapeutics shows better performance in seven factors, including higher institutional ownership and potential upside.

October 17, 2024
3 Articles